ASSESSMENT OF EFFICACY OF LEUKOTRIENE RECEPTOR ANTAGONISTS IN THERAPY OF BRONCHIAL ASTHMA IN CHILDREN
Abstract
The article provides data regarding the clinical efficacy and safety of leukotriene receptor antagonists in treatment of bronchial asthma in children. The only representative of this group that is allowed in Russia for treatment of children over 6 years of age is Montelukast. Approval of new 4 mg dosage of Montelukast for children from 2 years of age is expected in Russia in July 2009. Leukotriene receptor antagonists have a high safety profile and can be used as an alternative first-line therapy for persistent asthma.
Key words: leukotriene receptor antagonists, montelukast, bronchial asthma, children.
Key words: leukotriene receptor antagonists, montelukast, bronchial asthma, children.
About the Authors
Yu.G. Levina
Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L.S. Namazova-Baranova
Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Review
For citations:
Levina Yu., Namazova-Baranova L. ASSESSMENT OF EFFICACY OF LEUKOTRIENE RECEPTOR ANTAGONISTS IN THERAPY OF BRONCHIAL ASTHMA IN CHILDREN. Pediatric pharmacology. 2009;6(4):84-87.
Views:
618
Email this article 